Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 5/20 | 0.57 |
| ▸ | CETP | P11597 | 1/20 | 0.53 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540605 | 1.00 | TLR4 (0.57) | TLR4CETPDGKASELPAPP | |
| SCHEMBL2200474 | 1.00 | TLR4 (0.57) | TLR4CETPDGKASELPAPP | |
| SCHEMBL2200475 | 1.00 | TLR4 (0.57) | TLR4CETPDGKASELPAPP | |
| SCHEMBL28470234 | 1.00 | TLR4 (0.57) | TLR4CETPDGKASELPAPP | |
| SCHEMBL2598250 | 1.00 | TLR4 (0.57) | TLR4CETPDGKASELPAPP | |
| SCHEMBL65627 | 1.00 | TLR4 (0.57) | TLR4CETPDGKASELPAPP | |
| Formaldehyde SCHEMBL17748792 | 0.98 | TLR4 (0.55) | TLR4CETPDGKASELPAPP | |
| SCHEMBL2196892 | 0.96 | TLR4 (0.59) | TLR4CETP | |
| SCHEMBL2196896 | 0.96 | TLR4 (0.59) | TLR4CETP | |
| SCHEMBL5436079 | 0.96 | TLR4 (0.59) | TLR4CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861205-B1 | COMPOSITION INCLUDING A PYRIDINE DICARBOXYLIC ACID ESTER AND A GLUCOSE AND FATTY ACID ESTER. | OREAL (FR) | 2017-12-06 | — | — | EP | claimed |
| EP-2861205-A1 | COMPOSITION INCLUDING A PYRIDINE DICARBOXYLIC ACID ESTER AND A GLUCOSE AND FATTY ACID ESTER, METHOD THEREFOR, AND USE THEREOF | L'OREAL (FR) | 2015-04-22 | — | — | EP | claimed |
| WO-2013186485-A1 | COMPOSITION INCLUDING A PYRIDINE DICARBOXYLIC ACID ESTER AND A GLUCOSE AND FATTY ACID ESTER, METHOD THEREFOR, AND USE THEREOF | L'OREAL (FR) | 2013-12-19 | — | — | WO | claimed |
| EP-1837341-B1 | Derivative of glucose and vitamin F, compositions containing it, its uses to improve the state of hair | OREAL (FR) | 2011-08-03 | — | — | EP | claimed |
| US-7763587-B2 | Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process | L'OREAL S.A. (FR) | 2010-07-27 | — | — | US | claimed |
| EP-1837341-A1 | Derivative of glucose and vitamin F, compositions containing it, its uses and its preparation | L'Oréal (FR) | 2007-09-26 | — | — | EP | claimed |
| EP-1371658-B1 | Derivative of glucose and vitamin F, compositions containing it, its uses and its preparation | OREAL (FR) | 2007-09-12 | — | — | EP | claimed |
| US-20060165630-A1 | Use of amide or ester of sugar and of fatty acid, for treating and/or preventing dry skin | L'OREAL (FR) | 2006-07-27 | — | — | US | claimed |
| EP-1551362-A2 | USE OF AMIDE OR ESTER OF SUGAR AND OF FATTY ACID, FOR TREATING AND/OR PREVENTING DRY SKIN. | L'OREAL (FR) | 2005-07-13 | — | — | EP | claimed |
| WO-2004034958-A2 | USE OF AMIDE OR ESTER OF SUGAR AND OF FATTY ACID, FOR TREATING AND/OR PREVENTING DRY SKIN | L'OREAL (FR) | 2004-04-29 | — | — | WO | claimed |
| US-20040038912-A1 | Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process | L'OREAL S.A. (FR) | 2004-02-26 | — | — | US | claimed |
| EP-1371658-A1 | Derivative of glucose and vitamin F, compositions containing it, its uses and its preparation | L'OREAL (FR) | 2003-12-17 | — | — | EP | claimed |
| EP-2861205-A1 | COMPOSITION INCLUDING A PYRIDINE DICARBOXYLIC ACID ESTER AND A GLUCOSE AND FATTY ACID ESTER, METHOD THEREFOR, AND USE THEREOF | L'OREAL (FR) | 2015-04-22 | — | — | EP | disclosed |
| US-8729254-B2 | Derivative of glucose and vitamin F, compositions comprising it, uses and preparation process | L'OREAL (FR) | 2014-05-20 | — | — | US | disclosed |
| WO-2013186485-A1 | COMPOSITION INCLUDING A PYRIDINE DICARBOXYLIC ACID ESTER AND A GLUCOSE AND FATTY ACID ESTER, METHOD THEREFOR, AND USE THEREOF | L'OREAL (FR) | 2013-12-19 | — | — | WO | disclosed |
| EP-1837341-B1 | Derivative of glucose and vitamin F, compositions containing it, its uses to improve the state of hair | OREAL (FR) | 2011-08-03 | — | — | EP | disclosed |
| EP-1551362-A2 | USE OF AMIDE OR ESTER OF SUGAR AND OF FATTY ACID, FOR TREATING AND/OR PREVENTING DRY SKIN. | L'OREAL (FR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004034958-A2 | USE OF AMIDE OR ESTER OF SUGAR AND OF FATTY ACID, FOR TREATING AND/OR PREVENTING DRY SKIN | L'OREAL (FR) | 2004-04-29 | — | — | WO | disclosed |
| US-20040038912-A1 | Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process | L'OREAL S.A. (FR) | 2004-02-26 | — | — | US | disclosed |
| EP-1371658-A1 | Derivative of glucose and vitamin F, compositions containing it, its uses and its preparation | L'OREAL (FR) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038912-A1 | Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process | FASN, ELOVL6, ACSL6 | TLR4 2674/4885CETP 1496/4885DGKA 584/4885 |
| US-20060165630-A1 | Use of amide or ester of sugar and of fatty acid, for treating and/or preventing dry skin | CUTA, SCD5, SCD | TLR4 685/4885CETP 654/4885DGKA 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.